3 results
15215 Female sex worker experiences with intimate partner violence screening by health care providers
- Jessica L. Zemlak, Kamila A. Alexander, Deborah H. Wilson, Susan G. Sherman
-
- Journal:
- Journal of Clinical and Translational Science / Volume 5 / Issue s1 / March 2021
- Published online by Cambridge University Press:
- 30 March 2021, p. 134
-
- Article
-
- You have access Access
- Open access
- Export citation
-
ABSTRACT IMPACT: This work will inform the need for more trauma-informed approaches to violence screenings among marginalized populations by health care providers. OBJECTIVES/GOALS: Female sex workers (FSW) experience high rates of intimate partner violence (IPV) which may have negative reproductive health consequences. Routine IPV screening by healthcare providers (HCP) is recommended. This study examines how FSW experience IPV assessments by HCP. METHODS/STUDY POPULATION: This qualitative descriptive study is nested within EMERALD, a longitudinal cohort study of street-based FSW. EMERALD assesses a structural community-level intervention on HIV and STI risks among FSW. Participants were recruited for EMERALD using time-location sampling to identify a sampling frame of venues and times where sex work is likely to occur. Inclusion criteria for this qualitative study include: participating in EMERALD, age 18-49, and willingness to participate in one phone interview. Twenty-two semi-structured individual qualitative interviews were conducted. Two coders, using thematic analysis, applied deductive codes and inductive coding to identify themes. RESULTS/ANTICIPATED RESULTS: Three themes emerged from participant interviews regarding IPV screening. Inconsistent screening practices: Despite frequent reproductive health visits among participants, many women did not recall IPV screening by a HCP. Stigma as a barrier to disclosure: Women described feeling judged by HCP regarding their frequency of visits for reproductive concerns, sex work, and substance use and did not trust disclosing violence to HCP. Transactional health encounters: During visits, HCP were focused on addressing women’s immediate concerns; if the HCP did ask about IPV women felt the questions were asked part of a required protocol and not driven by a concern to deeply understand their lives. DISCUSSION/SIGNIFICANCE OF FINDINGS: FSW described inconsistent IPV screening practices by HPC. Participants expressed feeling stigmatized by HCP and that encounters with HCP did not foster trust for women to disclose IPV experiences. There is a need for HPC training in universal IPV screening focused on relationship and trust building to facilitate disclosure.
Contributors
-
- By Ghazi Al-Rawas, Vazken Andréassian, Tianqi Ao, Stacey A. Archfield, Berit Arheimer, András Bárdossy, Trent Biggs, Günter Blöschl, Theresa Blume, Marco Borga, Helge Bormann, Gianluca Botter, Tom Brown, Donald H. Burn, Sean K. Carey, Attilio Castellarin, Francis Chiew, François Colin, Paulin Coulibaly, Armand Crabit, Barry Croke, Siegfried Demuth, Qingyun Duan, Giuliano Di Baldassarre, Thomas Dunne, Ying Fan, Xing Fang, Boris Gartsman, Alexander Gelfan, Mikhail Georgievski, Nick van de Giesen, David C. Goodrich, Hoshin V. Gupta, Khaled Haddad, David M. Hannah, H. A. P. Hapuarachchi, Hege Hisdal, Kamila Hlavčová, Markus Hrachowitz, Denis A. Hughes, Günter Humer, Ruud Hurkmans, Vito Iacobellis, Elena Ilyichyova, Hiroshi Ishidaira, Graham Jewitt, Shaofeng Jia, Jeffrey R. Kennedy, Anthony S. Kiem, Robert Kirnbauer, Thomas R. Kjeldsen, Jürgen Komma, Leonid M. Korytny, Charles N. Kroll, George Kuczera, Gregor Laaha, Henny A. J. van Lanen, Hjalmar Laudon, Jens Liebe, Shijun Lin, Göran Lindström, Suxia Liu, Jun Magome, Danny G. Marks, Dominic Mazvimavi, Jeffrey J. McDonnell, Brian L. McGlynn, Kevin J. McGuire, Neil McIntyre, Thomas A. McMahon, Ralf Merz, Robert A. Metcalfe, Alberto Montanari, David Morris, Roger Moussa, Lakshman Nandagiri, Thomas Nester, Taha B. M. J. Ouarda, Ludovic Oudin, Juraj Parajka, Charles S. Pearson, Murray C. Peel, Charles Perrin, John W. Pomeroy, David A. Post, Ataur Rahman, Liliang Ren, Magdalena Rogger, Dan Rosbjerg, José Luis Salinas, Jos Samuel, Eric Sauquet, Hubert H. G. Savenije, Takahiro Sayama, John C. Schaake, Kevin Shook, Murugesu Sivapalan, Jon Olav Skøien, Chris Soulsby, Christopher Spence, R. ‘Sri’ Srikanthan, Tammo S. Steenhuis, Jan Szolgay, Yasuto Tachikawa, Kuniyoshi Takeuchi, Lena M. Tallaksen, Dörthe Tetzlaff, Sally E. Thompson, Elena Toth, Peter A. Troch, Remko Uijlenhoet, Carl L. Unkrich, Alberto Viglione, Neil R. Viney, Richard M. Vogel, Thorsten Wagener, M. Todd Walter, Guoqiang Wang, Markus Weiler, Rolf Weingartner, Erwin Weinmann, Hessel Winsemius, Ross A. Woods, Dawen Yang, Chihiro Yoshimura, Andy Young, Gordon Young, Erwin Zehe, Yongqiang Zhang, Maichun C. Zhou
- Edited by Günter Blöschl, Technische Universität Wien, Austria, Murugesu Sivapalan, University of Illinois, Urbana-Champaign, Thorsten Wagener, University of Bristol, Alberto Viglione, Technische Universität Wien, Austria, Hubert Savenije, Technische Universiteit Delft, The Netherlands
-
- Book:
- Runoff Prediction in Ungauged Basins
- Published online:
- 05 April 2013
- Print publication:
- 18 April 2013, pp ix-xiv
-
- Chapter
- Export citation
Biocompatible Ceramics for Implants Based on Calcium Phosphates
- Tatiana Safronova, Valery I. Putlayev, Alexander G. Veresov, Anton V. Kuznetsov, Mikhail A. Shekhirev, Kamila A. Agahi
-
- Journal:
- MRS Online Proceedings Library Archive / Volume 951 / 2006
- Published online by Cambridge University Press:
- 01 February 2011, 0951-E12-31
- Print publication:
- 2006
-
- Article
- Export citation
-
Hydroxyapatite (HAp), tricalcium phosphate (TCP) and calcium pyrophosphate (CPP) are known to be among calcium phosphates used in clinical medicine due to their biocompatibility. HAp and other complex calcium phosphate salts are the end-products of the biological mineralization process. Calcium pyrophosphate Ca2P2O7 (β-CPP) is one of the intermediate products involved in this process. The biological response with respect to new bone formation is quite similar for CPP and HAp. Sintered CPP has better biological responses, and, thus, a great potential as a biodegradable bone substitute. The rate of biodegradation depends on: (i) material texture (porosity type and level), (ii) quality of biodegradation phase (phase composition, grain size, properties of grain boundaries). Several sources for CPP phase in ceramics can be assumed. CPP phase may come from frit (CaO-P2O5, Ca/P=0.2-0.75) used as a sintering additive. Ceramics can be fabricated from powder of CPP with Na4P2O7 as sintering additive, via interaction between H3PO4 or (NH4)2HPO4 and porous HAp at high temperature after soaking it in the former solutions. The aim of the present work was focused on fabrication of multiphase ceramics with enhanced resorptivity due to presence of CPP phase and investigation of processes leading to formation of the multiphase ceramics based on HAp and CPP originated from CaHPO4. Ceramic materials have been made from mixtures of powders of stoihiometric HAp (Ca/P=1.67) and monetite (CaHPO4, Ca/P=1). Powders of HAp and monetite were synthesized by means of wet chemical precipitation from aqueous solutions of Ca(NO3)2*4H2O and (NH4)2HPO4 at 60 °C and pH=9 for HAp and pH=4-5 for monetite. Component ratio HAp:monetite was varied from 0:100 to 100:0 % with a step of 20%. Powders of raw materials and the mixtures were tested by means of XRD, TG, DTG, SEM, dilatometry. Linear shrinkage, density and microstructure of samples of ceramic materials sintered at 900, 1000, 1100°C with isothermal holding during 6 hours were tested. Complicated consequence of phase transformations took place during heating the the mixtures from 20 to 1200 C. The CPP (Ca/P=1, converted from CaHPO4 at 400-500°C ) reacts with HAp (Ca/P=1.67) causing additional weight loss in the region of 600-1050°C due to solid state reaction leading to TCP (Ca/P=1.55) formation. Linear shrinkage of HAp at 1100°C after 6 hours was found to be about 21%; for Ca2P2O7 formed from monetite, and for the mixtures - less than 11%. Resulted ceramics with the phase composition of HAp, CPP and TCP, i.e. with a different content of degradable phase and different ratio of CPP/TCP, can be treated as a biocompatible bioactive material with a tunable rate and limit of biodegradation.